In anti-PD-1 immunotherapy, treatment with the PD-1 blockade interrupted the inhibitory effect mediated by PD-1/PD-L1 axis and restored activity of lymphocytes, which are the main effector cells with an anti-tumor function (19). This evidence concerns the gene PDCD1 and neoplasm.